Free Trial
→ Financial legend: “This is bad, really bad...” (From Weiss Ratings) (Ad)tc pixel
NASDAQ:VTGN

VistaGen Therapeutics Q2 2027 Earnings Date & Estimates

VistaGen Therapeutics logo
$0.20 -0.01 (-6.10%)
Closing price 04:00 PM Eastern
Extended Trading
$0.20 0.00 (0.00%)
As of 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

VistaGen Therapeutics is estimated to report Q2 2027 earnings on Thursday, November 12, 2026. The conference call is scheduled for 5:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q2 2027
Announcement Date
Conference Call
5:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from VistaGen Therapeutics in Q2 2027

VistaGen Therapeutics is expected to post earnings of -$0.37 per share on revenue of $0.50 million. In the same quarter a year earlier VistaGen Therapeutics reported -$0.54 per share on revenue of $0.26 million. VistaGen Therapeutics last reported on August 14, 2026, posting -$0.30 per share and beating the -$0.3650 consensus estimate. VistaGen Therapeutics has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.37
Expected Revenue
$0.50 million
Prior-Year EPS
-$0.54
Prior-Year Revenue
$0.26 million
Expected Revenue Growth
+93.8%

Recent Track Record

Last Reported
Q1 2027
Last Quarter EPS
-$0.30 (Beat by +$0.0650)
Last Quarter Revenue
$1.48 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q2 2027 Call

VistaGen Therapeutics Q2 2027 Earnings FAQ

VistaGen Therapeutics (NASDAQ:VTGN) is estimated to report Q2 2027 earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

VistaGen Therapeutics' Q2 2027 earnings conference call is scheduled for Thursday, November 12, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect VistaGen Therapeutics to post earnings of -$0.37 per share for Q2 2027.

The consensus revenue estimate for VistaGen Therapeutics is $0.50 million for Q2 2027.

VistaGen Therapeutics Earnings Headlines

VistaGen Therapeutics (NASDAQ:VTGN) Share Price Crosses Below 50 Day Moving Average - Should You Sell?
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095070
Analysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (CDXS) and VistaGen Therapeutics (VTGN)
September 24, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CDXS/pressreleases/4771757/analysts-have-conflicting-sentiments-on-these-healthcare-companies-codexis-cdxs-and-vistagen-therapeutics-vtgn/
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered. Buried inside is what some call the legal groundwork for the biggest change to American money in over a century, with a key Treasury vote potentially as soon as January 18. Ian King, Chief Strategist at Strategic Fortunes, breaks down what the order could mean for the dollar and the financial system.tc pixel
October 16 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder
September 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/24/3368189/0/en/vistagen-reports-positive-findings-supporting-fasedienol-s-potential-in-very-severe-social-anxiety-disorder.html
Vistagen Reports Preliminary Data From Fasedienol Phase 3 Extension Study; Stock Up
September 22, 2026  |  rttnews.comhttps://www.rttnews.com/3692973/vistagen-reports-preliminary-data-from-fasedienol-phase-3-extension-study-stock-up.aspx
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366338/0/en/vistagen-announces-preliminary-positive-data-from-open-label-extension-portion-of-palisade-4-phase-3-study-of-fasedienol-for-the-acute-treatment-of-social-anxiety-disorder.html
See More VistaGen Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like VistaGen Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on VistaGen Therapeutics and other key companies, straight to your email.

About VistaGen Therapeutics

VistaGen Therapeutics (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with an emphasis on anxiety, depression and related conditions. The company is headquartered in South San Francisco, California, and conducts its development activities primarily in the United States.

VistaGen’s lead product candidate is fasedienol, also known as PH94B, an investigational neuroactive nasal spray being developed for the treatment of social anxiety disorder and other anxiety-related conditions. The company’s approach is intended to provide rapid, non-systemic treatment through nasal administration. Fasedienol remains an investigational product and has not been approved for commercial sale.

The company also maintains a broader neuroscience pipeline that has included other intranasal drug candidates, including PH80, as it evaluates potential treatments for psychiatric and neurological conditions. VistaGen’s programs are subject to clinical testing and regulatory review, and their development status may change as additional data become available. Shawn Singh serves as the company’s chief executive officer.

View VistaGen Therapeutics Profile
Earnings Tools